Patent March-In Power: Government Likes Having, Not Using It
This article was originally published in The Pink Sheet Daily
Executive Summary
GAO report concludes that although never employed, Bayh-Dole power "is particularly valuable as leverage in informal discussions."
You may also be interested in...
NIH Resists “March In” On Norvir Patents Based On Pricing Concerns
NIH will not invoke its “march-in” authority under the Bayh-Dole Act to allow broader access to Norvir patents, Director Francis Collins says in response to a petition.
NIH Will Not “March-In” On Pfizer’s Xalatan
Similar to its decision in the Norvir case, NIH says availability, not price, is test of whether the agency can “march-in” on a company’s exclusivity.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.